Elanco Animal Health IncorporatedELANNYSE
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank74
3Y CAGR+20.6%
5Y CAGR-30.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+20.6%/yr
vs +15.6%/yr prior
5Y CAGR
-30.6%/yr
Recent acceleration
Acceleration
+4.9pp
Accelerating
Percentile
P74
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.49% |
| Q3 2025 | -3.26% |
| Q2 2025 | -2.13% |
| Q1 2025 | 16.05% |
| Q4 2024 | -6.90% |
| Q3 2024 | -2.25% |
| Q2 2024 | 2.30% |
| Q1 2024 | 10.13% |
| Q4 2023 | -8.14% |
| Q3 2023 | 6.17% |
| Q2 2023 | 0.00% |
| Q1 2023 | 1.25% |
| Q4 2022 | 2.56% |
| Q3 2022 | -4.88% |
| Q2 2022 | 1.23% |
| Q1 2022 | -11.96% |
| Q4 2021 | -2.13% |
| Q3 2021 | 0.00% |
| Q2 2021 | 5.62% |
| Q1 2021 | -21.03% |
| Q4 2020 | 27.92% |
| Q3 2020 | 48.32% |
| Q2 2020 | -11.08% |
| Q1 2020 | -0.74% |
| Q4 2019 | -3.72% |
| Q3 2019 | 1.60% |
| Q2 2019 | 7.33% |
| Q1 2019 | 4.91% |
| Q4 2018 | 3.74% |
| Q3 2018 | -4.07% |
| Q2 2018 | -5.83% |
| Q1 2018 | 5.16% |
| Q4 2017 | 0.16% |
| Q3 2017 | -3.21% |
| Q2 2017 | 0.00% |
| Q1 2017 | 0.00% |